487 related articles for article (PubMed ID: 26484003)
1. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D; Bronte G; Passiglia F; Calò V; Castiglia M; Di Piazza F; Barraco N; Cangemi A; Catarella MT; Insalaco L; Listì A; Maragliano R; Massihnia D; Perez A; Toia F; Cicero G; Bazan V
Anal Cell Pathol (Amst); 2015; 2015():690916. PubMed ID: 26484003
[TBL] [Abstract][Full Text] [Related]
2. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
Jordan MA
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
[TBL] [Abstract][Full Text] [Related]
4. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
Aparicio LM; Pulido EG; Gallego GA
Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in microtubule-stabilizing agents.
Cao YN; Zheng LL; Wang D; Liang XX; Gao F; Zhou XL
Eur J Med Chem; 2018 Jan; 143():806-828. PubMed ID: 29223097
[TBL] [Abstract][Full Text] [Related]
6. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
7. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
8. Microtubule-associated proteins as targets in cancer chemotherapy.
Bhat KM; Setaluri V
Clin Cancer Res; 2007 May; 13(10):2849-54. PubMed ID: 17504982
[TBL] [Abstract][Full Text] [Related]
9. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Chen JG; Horwitz SB
Cancer Res; 2002 Apr; 62(7):1935-8. PubMed ID: 11929805
[TBL] [Abstract][Full Text] [Related]
10. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
11. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
[TBL] [Abstract][Full Text] [Related]
12. Microtubules and Cell Division: Potential Pharmacological Targets in Cancer Therapy.
Sebastian J; Rathinasamy K
Curr Drug Targets; 2023; 24(11):889-918. PubMed ID: 37519203
[TBL] [Abstract][Full Text] [Related]
13. Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability.
Wu J; He Z; Wang DL; Sun FL
Cell Cycle; 2016 Nov; 15(21):2980-2991. PubMed ID: 27715397
[TBL] [Abstract][Full Text] [Related]
14. Epothilones: mechanism of action and biologic activity.
Goodin S; Kane MP; Rubin EH
J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
[TBL] [Abstract][Full Text] [Related]
15. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
16. New tubulin targeting agents currently in clinical development.
Carlson RO
Expert Opin Investig Drugs; 2008 May; 17(5):707-22. PubMed ID: 18447597
[TBL] [Abstract][Full Text] [Related]
17. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
18. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
19. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
Fürst R; Vollmar AM
Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
[TBL] [Abstract][Full Text] [Related]
20. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag DM; McQueney PA; Zhu J; Hensens O; Koupal L; Liesch J; Goetz M; Lazarides E; Woods CM
Cancer Res; 1995 Jun; 55(11):2325-33. PubMed ID: 7757983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]